{"id":49170,"date":"2025-11-27T21:26:13","date_gmt":"2025-11-27T13:26:13","guid":{"rendered":"https:\/\/flcube.com\/?p=49170"},"modified":"2025-11-27T21:26:14","modified_gmt":"2025-11-27T13:26:14","slug":"cspcs-jmt206-wins-nmpa-nod-for-actrii-targeted-weight-management","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49170","title":{"rendered":"CSPC&#8217;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that its self\u2011developed <strong>recombinant fully human anti\u2011ActRIIA\/IIB monoclonal antibody, JMT206<\/strong>, received approval from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> to conduct clinical trials for <strong>weight management<\/strong> in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to <strong>GLP\u20111 receptor agonists<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>JMT206 (anti\u2011ActRIIA\/IIB monoclonal antibody)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group (1093.HK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Weight management in obesity\/overweight with \u22651 weight\u2011related comorbidity<\/td><\/tr><tr><td><strong>Application Accepted<\/strong><\/td><td>September\u202f2025<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Initiate Phase\u202fI dose\u2011escalation study Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Dual targeting of <strong>Activin Receptor Type IIA (ActRIIA)<\/strong> and <strong>Type IIB (ActRIIB)<\/strong>, blocking binding of <strong>Activin A, Myostatin (GDF8), and GDF11<\/strong><\/li>\n\n\n\n<li><strong>Effect:<\/strong> Inhibits downstream signaling to <strong>reduce muscle loss, promote skeletal muscle maintenance\/growth, increase muscle mass, and reduce fat<\/strong><\/li>\n\n\n\n<li><strong>Strategic Angle:<\/strong> <strong>May enhance GLP\u20111 RA efficacy<\/strong> by preserving lean muscle mass during weight loss, addressing a key limitation of current obesity therapies<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> First <strong>ActRII\u2011targeted antibody<\/strong> to enter clinical development for obesity in China; potential <strong>best\u2011in\u2011class muscle\u2011preserving weight loss agent<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Obesity Patients<\/strong><\/td><td><strong>180\u202fmillion<\/strong> (2024)<\/td><\/tr><tr><td><strong>GLP\u20111 RA Market Size (China)<\/strong><\/td><td>\u00a542\u202fbillion (US$5.8\u202fbillion)<\/td><\/tr><tr><td><strong>Muscle Loss on GLP\u20111s<\/strong><\/td><td><strong>25\u201140%<\/strong> of weight loss is lean mass<\/td><\/tr><tr><td><strong>Muscle\u2011Preservation Unmet Need<\/strong><\/td><td><strong>&gt;50%<\/strong> of prescribers cite muscle loss as key concern<\/td><\/tr><tr><td><strong>Peak Sales Forecast (JMT206)<\/strong><\/td><td><strong>\u00a55.0\u20117.0\u202fbillion<\/strong> (~US$680\u2011950\u202fmillion) by 2033<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>15\u201120% of GLP\u20111 combination therapy segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong> <strong>No approved ActRII inhibitors<\/strong> for obesity; <strong>BMS\u2019s bimagrumab<\/strong> (ActRIIA\/IIB) in Phase\u202f3 but not yet in China; CSPC\u2019s first\u2011mover advantage<\/li>\n\n\n\n<li><strong>Reimbursement Path:<\/strong> NMPA acceptance of novel mechanism may qualify for <strong>Breakthrough Therapy Designation<\/strong>; potential NRDL inclusion based on GLP\u20111 synergy data<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Phase\u202fI safety and PK\/PD data expected <strong>Q4\u202f2026<\/strong>; combination study with semaglutide planned <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding JMT206\u2019s clinical development, regulatory pathway, and commercial potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the obesity therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\/IIB monoclonal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49178,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,855,4445,86],"class_list":["post-49170","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093","tag-metabolic-disease","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\/IIB monoclonal antibody, JMT206, received approval from China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for weight management in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to GLP\u20111 receptor agonists.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49170\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\/IIB monoclonal antibody, JMT206, received approval from China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for weight management in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to GLP\u20111 receptor agonists.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49170\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T13:26:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-27T13:26:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management\",\"datePublished\":\"2025-11-27T13:26:13+00:00\",\"dateModified\":\"2025-11-27T13:26:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2704.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Metabolic disease\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49170#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49170\",\"name\":\"CSPC's JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2704.webp\",\"datePublished\":\"2025-11-27T13:26:13+00:00\",\"dateModified\":\"2025-11-27T13:26:14+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\\\/IIB monoclonal antibody, JMT206, received approval from China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for weight management in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to GLP\u20111 receptor agonists.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49170\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2704.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC's JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49170#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\/IIB monoclonal antibody, JMT206, received approval from China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for weight management in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to GLP\u20111 receptor agonists.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49170","og_locale":"en_US","og_type":"article","og_title":"CSPC's JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\/IIB monoclonal antibody, JMT206, received approval from China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for weight management in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to GLP\u20111 receptor agonists.","og_url":"https:\/\/flcube.com\/?p=49170","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T13:26:13+00:00","article_modified_time":"2025-11-27T13:26:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49170#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49170"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management","datePublished":"2025-11-27T13:26:13+00:00","dateModified":"2025-11-27T13:26:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49170"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49170#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp","keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093","Metabolic disease","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49170#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49170","url":"https:\/\/flcube.com\/?p=49170","name":"CSPC's JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49170#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49170#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp","datePublished":"2025-11-27T13:26:13+00:00","dateModified":"2025-11-27T13:26:14+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self\u2011developed recombinant fully human anti\u2011ActRIIA\/IIB monoclonal antibody, JMT206, received approval from China\u2019s National Medical Products Administration (NMPA) to conduct clinical trials for weight management in obesity or overweight patients with comorbidities, positioning it as a potential adjunct to GLP\u20111 receptor agonists.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49170#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49170"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49170#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp","width":1080,"height":608,"caption":"CSPC's JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49170#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2704.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49170"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49170\/revisions"}],"predecessor-version":[{"id":49179,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49170\/revisions\/49179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49178"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}